Talon Pharmaceutical Services is a drug development company focused on creating innovative treatments for central nervous system disorders and challenging bacterial infections. Their multiphore discovery platform allows drugs to interact with multiple disease targets, either by incorporating multiple pharmacophores into a single molecule or through a unique combination of different mechanisms of action. Their lead product, TPS-100, is designed to treat motor coordination and neurodegeneration in ARSACS and is currently in the preclinical stage. Additionally, Talon is working on two other small molecules for the treatment of ALS and multi-drug resistant bacteria, which are in the discovery stage. By identifying new therapies for rare CNS disorders and multidrug-resistant gram-negative bacterial infections, Talon Pharmaceuticals aims to improve patient quality of life and save lives.